Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 20 /hr

★★★★★

☆☆☆☆☆

Hire Dr. Biancastella C.

United Kingdom

USD 20 /hr

Cancer geneticist with 10+ years of experience in scientific writing and editing - both English and Italian

Profile Summary

During the course of her BSc in Molecular Biology from the University of Padua, Italy, Dr Biancastella Cereser developed her first interest on breast cancer in the group of Prof Antonino Carbone and Dr Annunziata Gloghini in the National Cancer Institute Aviano, Italy. She went on to achieve a MSc in Molecular Biology from the University of Padua, in collaboration with the group of Dr Maria Grazia Masucci in the Karolinska Institute, Sweden. In 2006, Dr Cereser joined Queen Mary University of London, where she completed a PhD in the group of Prof Ken Parkinson, investigating the non-canonical functions of telomerase in keratinocytes. She then joined Prof Malcolm Alison, Dr Stuart McDonald and Sir Nick Wright's group in the same university, where as a member of staff she developed particular expertise in the genetic analysis of epithelial premalignant diseases, in particular colon adenomas and ductal carcinoma in situ. Dr Cereser joined Imperial College London in 2016 as a research associate in Prof Justin Stebbing group in the Department of Surgery and Cancer. Dr Cereser is also a Fellow of the Higher Education Academy (FHEA)

Subject Matter Expertise

• ★ Cancer Research
• ☆ Molecular Biology
• ☆ Genetics
• ☆ Cell Culture
• ☆ Italian
• ☆ Breast Cancer
• ☆ Colorectal Cancer

Services

• Writing
• Research
• Data & AI

Writing Clinical Trial Documentation, Technical Writing, Newswriting

Research Secondary Data Collection

Data & AI Statistical Analysis

Work Experience

Research Associate

Imperial College London

July 2016 - Present

Postdoctoral Research Assistant

Queen Mary University of London

2010 - 2016

Education

PhD

Queen Mary University of London

2006 - 2010

MSc in Molecular Biology

Università degli Studi di Padova

2003 - 2005

Certifications

• Certification details not provided.

Publications

JOURNAL ARTICLE

Baker, A.-M., Gabbutt, C., Williams, M.J., Cereser, B., Jawad, N., Rodriguez-Justo, M., Jansen, M., Barnes, C.P., Simons, B.D., McDonald, S.A.C., et al.(2019). Crypt fusion as a homeostatic mechanism in the human colon . Gut.

Baker, A.-M., Cereser, B., Melton, S., Fletcher, A.G., Rodriguez-Justo, M., Tadrous, P.J., Humphries, A., Elia, G., McDonald, S.A.C., Wright, N.A., et al.(2019). Erratum: Quantification of Crypt and Stem Cell Evolution in the Normal and Neoplastic Human Colon (Quantification of Crypt and Stem Cell Evolution in the Normal and Neoplastic Human Colon (2014) 8(4) (940–947), (S2211124714005889), (10.1016/j.celrep.2014.07.019)) . Cell Reports. 27. (8). p. 2524.

Chandrasinghe, P., Cereser, B., Moorghen, M., Al Bakir, I., Tabassum, N., Hart, A., Stebbing, J., Warusavitarne, J.(2018). Role of SMAD proteins in colitis-associated cancer: From known to the unknown . Oncogene. 37. (1). p. 1-7.

(2018). Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients? . Oncotarget. 9. (10). p. 9456-9467.

Cereser, B., Jansen, M., Austin, E., Elia, G., McFarlane, T., van Deurzen, C.H.M., Sieuwerts, A.M., Daidone, M.G., Tadrous, P.J., Wright, N.A., et al.(2018). Analysis of clonal expansions through the normal and premalignant human breast epithelium reveals the presence of luminal stem cells . Journal of Pathology. 244. (1). p. 61-70.

Carter, P., Alifrangis, C., Cereser, B., Chandrasinghe, P., Belluz, L.B., Moderau, N., Poyia, F., Schwartzberg, L.S., Tabassum, N., Wen, J., et al.(2018). Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans . Oncotarget. 9. (25). p. 17589-17596.

Carter, P., Alifrangis, C., Cereser, B., Chandrasinghe, P., Belluz, L.B., Fotopoulou, C., Frilling, A., Herzog, T., Moderau, N., Tabassum, N., et al.(2018). Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy . Oncotarget. 9. (5). p. 6007-6014.

Carter, P., Alifrangis, C., Chandrasinghe, P., Cereser, B., Belluz, L.B., Leo, C.A., Moderau, N., Tabassum, N., Warusavitarne, J., Krell, J., et al.(2018). The benefit of tumor molecular profiling on predicting treatments for colorectal adenocarcinomas . Oncotarget. 9. (13). p. 11371-11376.

Carter, P., Alifrangis, C., Cereser, B., Chandrasinghe, P., Del Bel Belluz, L., Fotopoulou, C., Frilling, A., Herzog, T., Moderau, N., Tabassum, N., et al.(2018). Correction: Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy [Oncotarget, 9 (2018) (6007-6014)] DOI:10.18632/oncotarget.23675 . Oncotarget. 9. (19). p. 15164.

Carter, P., Alifrangis, C., Cereser, B., Chandrasinghe, P., Del Bel Belluz, L., Herzog, T., Levitan, J., Moderau, N., Schwartzberg, L., Tabassum, N., et al.(2018). Correction: Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients? [Oncotarget, 9 (2018) (9456-9467)] DOI:10.18632/oncotarget.24258 . Oncotarget. 9. (19). p. 15166.

Carter, P., Alifrangis, C., Chandrasinghe, P., Cereser, B., Del Bel Belluz, L.D., Leo, C.A., Moderau, N., Tabassum, N., Warusavitarne, J., Krell, J., et al.(2018). Correction: The benefit of tumor molecular profiling on predicting treatments for colorectal adenocarcinomas [Oncotarget, 9 (2018) (11371-11376)] DOI:10.18632/oncotarget.24257 . Oncotarget. 9. (19). p. 15165.

Alifrangis, C., Carter, P., Cereser, B., Chandrasinghe, P., Belluz, L.D.B., Lim, E., Moderau, N., Poyia, F., Tabassum, N., Zhang, H., et al.(2018). Investigating the benefits of molecular profiling of advanced nonsmall cell lung cancer tumors to guide treatments . Oncotarget. 9. (16). p. 12805-12811.

Lavery, D.L., Martinez, P., Gay, L.J., Cereser, B., Novelli, M.R., Rodriguez-Justo, M., Meijer, S.L., Graham, T.A., McDonald, S.A.C., Wright, N.A., et al.(2016). Evolution of oesophageal adenocarcinoma from metaplastic columnar epithelium without goblet cells in Barrett's oesophagus . Gut. 65. (6). p. 907-913.

Wong, P.-P., Demircioglu, F., Ghazaly, E., Alrawashdeh, W., Stratford, M.R.L., Scudamore, C.L., Cereser, B., Crnogorac-Jurcevic, T., McDonald, S., Elia, G., et al.(2015). Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread . Cancer Cell. 27. (1). p. 123-137.

Baker, A.-M., Cereser, B., Melton, S., Fletcher, A.G., Rodriguez-Justo, M., Tadrous, P.J., Humphries, A., Elia, G., McDonald, S.A.C., Wright, N.A., et al.(2014). Quantification of crypt and stem cell evolution in the normal and neoplastic human colon . Cell Reports. 8. (4). p. 940-947.

Humphries, A., Cereser, B., Gay, L.J., Miller, D.S.J., Das, B., Gutteridge, A., Elia, G., Nye, E., Jeffery, R., Poulsom, R., et al.(2013). Lineage tracing reveals multipotent stem cells maintain human adenomas and the pattern of clonal expansion in tumor evolution . Proceedings of the National Academy of Sciences of the United States of America. 110. (27).

Parkinson, E.K., Fitchett, C., Cereser, B.(2009). Dissecting the non-canonical functions of telomerase . Cytogenetic and Genome Research. 122. (3-4). p. 273-280.

Stavropoulou, V., Vasquez, V., Cereser, B., Freda, E., Masucci, M.G.(2006). TPPII promotes genetic instability by allowing the escape from apoptosis of cells with activated mitotic checkpoints . Biochemical and Biophysical Research Communications. 346. (2). p. 415-425.